Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey
| Autor: | Dewi Vernerey, Aurelie Catteau, Afsaneh Barzi, Graham M. Poage, Efrat Dotan, Anup Kasi, Manju George |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Adjuvant chemotherapy Population Article Internal medicine medicine tumor microenvironment In patient education Prospective cohort study RC254-282 education.field_of_study business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens colonic neoplasms Tumor site Clinical Practice Physician survey oncologists surveys and questionnaires prognosis business Stage ii colon cancer |
| Zdroj: | Cancers Volume 13 Issue 21 Cancers, Vol 13, Iss 5467, p 5467 (2021) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13215467 |
| Popis: | Simple Summary Selection of appropriate stage II colon cancer patients for adjuvant chemotherapy (AC) is controversial. A novel immune response classifier has previously been validated to refine patient selection, but its impact on oncologist treatment planning had yet to be described. In this survey, all but one oncologist altered clinical practice recommendations, and recommendations for AC prescriptions were reduced by half (among the Immunoscore-high cases (low recurrence risk)). This study revealed that the Immunoscore results could significantly decrease AC use in patients with stage II colon cancer who may not benefit from it, thereby reducing the administration of nonvalue care. Abstract Background: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists’ recommendations for management of patients with stage II colon cancer. Methods: De-identified vignettes of 10 patients with stage II colon cancer were presented to 25 practicing medical oncologists. Each participant completed surveys indicating recommendations for adjuvant chemotherapy and surveillance strategies. An educational session was subsequently conducted, and the same patient profiles were re-presented but included immunoscore results. Participants were again asked to provide their recommendations. A participant was counted as influenced if their responses were altered after immunoscore test results were provided. Results: All but one participant (96%) altered a management recommendation for ≥1 case. For individual cases, a mean of 55% (range, 40–80%) of participants altered their recommendations for adjuvant chemotherapy and/or surveillance. For the immunoscore-high cases (low-risk of recurrence), recommendations for adjuvant chemotherapy use decreased from 60% to 31%. Conclusions: These results indicate a willingness by oncologists to integrate immunoscore information into clinical practice recommendations. Incorporation of immunoscore data resulted in the reduction of nonvalue care in the simulated population. Confirmation in prospective studies is planned. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|